OKYO Pharma’s lead asset OK-101 receives United States Adopted Name “urcosimod”

(Image Credit: AdobeStock)

Okyo Pharma announced that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) “urcosimod”.

The USAN program, jointly managed by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA), assigns unique nonproprietary names to pharmaceutical substances to ensure clarity in medical communication.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways, critical to addressing ocular conditions such as neuropathic corneal pain and dry eye disease.

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response.

Gary S Jacob, PhD, CEO of Okyo Pharma commented on the USAN assignment in a press release from the company.

“We are thrilled to announce that OK-101 has been granted the name urcosimod, marking an important step in its development as a therapeutic option for patients suffering from serious ocular conditions,” said Jacob. “Urcosimod is currently in a Phase 2 clinical trial for neuropathic corneal pain, an area of significant unmet medical need. This follows the encouraging results observed in our prior Phase 2 trial of urcosimod for dry eye disease, where the drug demonstrated strong pain reducing effects and a favorable safety profile.”

The ongoing Phase 2 trial for neuropathic corneal pain was initiated in October 2024 with top-line results planned to release in Q4 2025.

Reference:

1. OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod. Published February 12, 2025. Accessed February 12, 2025.https://okyopharma.com/okyo-pharma-announces-ok-101-officially-assigned-usan-urcosimod/